hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06363864 id: LL-IRB-2401 briefTitle: Investigation of Metabolomics Differences Between Metabolic Syndrome and Healthy Individuals in Taiwan overallStatus: NOT_YET_RECRUITING date: 2024-04-14 date: 2029-10-31 date: 2029-10-31 date: 2024-04-12 date: 2024-04-12 name: Leeuwenhoek Laboratories Co. Ltd. class: INDUSTRY briefSummary: The prevalence of metabolic syndrome in Taiwan has been increasing yearly. In this project, the database of blood test results from healthy and metabolic syndromes individuals will be analyzed to identify the small molecules related to the severity of metabolic syndrome. These identified small molecules could be used as biomarkers to predict the development of metabolic syndromes in the future. conditions: Metabolic Syndrome studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 1200 type: ESTIMATED measure: Concentration changes of small molecules in blood. sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06363851 id: Kylo-11-I-C01 briefTitle: Single-ascending Dose Study of Kylo-11 in Healthy Subjects overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2025-05-31 date: 2025-11-30 date: 2024-04-12 date: 2024-04-12 name: Kylonova (Xiamen) Biopharma co., LTD. class: INDUSTRY briefSummary: This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-11 will be evaluated in approximately 60 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects. conditions: Cardiovascular Diseases studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: Kylo-11 name: Placebo measure: Incidence of adverse events measure: Incidence of adverse events measure: Pharmacokinetics (PK) parameter of maximum observed concentration (Cmax) measure: PK parameter of time of maximum observed concentration (Tmax) measure: PK parameter of area under the concentration time curve (AUC) measure: Change in serum Lp(a) over time measure: Percent change in serum Lp(a) over time sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Chengdu Xinhua Hospital city: Chengdu state: Sichuan zip: 610000 country: China name: Xiaolan Yong role: CONTACT lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06363838 id: ordu eah briefTitle: Evaluation of Neuromuscular Morphometry of the Vaginal Wall overallStatus: COMPLETED date: 2019-12-01 date: 2020-06-25 date: 2020-06-30 date: 2024-04-12 date: 2024-04-12 name: Gaziosmanpasa Research and Education Hospital class: OTHER_GOV name: T.C. ORDU ÜNİVERSİTESİ briefSummary: In this prospective study, women aged between 40 and 75 years who had not undergone any vaginal surgery and had not undergone any abdominal prolapse surgery were included. Thirty-one women diagnosed with rectocele on examination were included in the study group. Thirty-one patients who underwent vaginal intervention and hysterectomy for reasons other than rectocele (colposcopy, conization, etc.) without anterior or posterior wall prolapse were included in the control group. conditions: Pelvic Organ Prolapse studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 62 type: ACTUAL measure: epithelial thickness measure: smooth muscle density sex: FEMALE minimumAge: 40 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hakan Timur city: Ordu country: Turkey lat: 40.97782 lon: 37.89047 hasResults: False
nctId: NCT06363825 id: MRCTA,ECFAH Of FMU[2024]373 briefTitle: A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma overallStatus: RECRUITING date: 2024-04-12 date: 2026-04-11 date: 2027-05-11 date: 2024-04-12 date: 2024-04-17 name: Fujian Medical University class: OTHER briefSummary: To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load conditions: Advanced Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 57 type: ESTIMATED name: camrelizumab measure: Objective response rate (ORR) measure: Disease control rate (DCR) measure: Progression-free survival (PFS) measure: Tumor progression time (TTP) measure: Overall survival (OS) measure: AE sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xinhua Chen status: RECRUITING city: Fuzhou country: China name: Yiping Chen role: CONTACT phone: 13805066904 lat: 26.06139 lon: 119.30611 hasResults: False
nctId: NCT06363812 id: The POST briefTitle: Probability of OncotypeDx to Reallocate as Low or High Risk of Recurrence Breast Cancer Patients With Uncertain Biology overallStatus: ACTIVE_NOT_RECRUITING date: 2018-03-08 date: 2021-05-15 date: 2024-12-31 date: 2024-04-12 date: 2024-04-15 name: Fondazione Sandro Pitigliani class: OTHER name: Genomic Health®, Inc. name: Istituto Toscano Tumori briefSummary: In some cases of hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative early breast cancer the benefit of adding adjuvant chemotherapy to hormonal treatment, estimated on the basis of the classical clinico-pathological parameters, is unclear. In these cases the application of a genomic test could be useful in guiding the therapeutic choice. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 258 type: ACTUAL measure: the proportion of tumor samples with a useful OncotypeDx measure: the proportion of patients in which the result of the test has induced a modification in the initial treatment plan measure: the proportion of tumor samples with an intermediate risk or not evaluable at OncotypeDx sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital of Prato city: Prato zip: 59100 country: Italy lat: 43.8805 lon: 11.09699 hasResults: False
nctId: NCT06363799 id: OST1_010 briefTitle: Osteopathic Protocol for Insomnia in College Students overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2024-12 date: 2024-12 date: 2024-04-12 date: 2024-04-29 name: Escola Superior de Tecnologia da Saúde do Porto class: OTHER briefSummary: In this randomized controlled experimental trial, it is aimed to determine the effectiveness of an osteopathic protocol treatment for insomnia in college students. In this study, will be used the Compression of 4th ventricle (CV4) and the diaphragmatic breathing technique. conditions: Insomnia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 20 type: ESTIMATED name: 4th ventricle compression technique and diaphragmatic breathing name: Sham Technique measure: Change from the baseline insomnia episodes and symptoms through Pittsburgh questionnaire score sex: ALL minimumAge: 18 Years maximumAge: 28 Years stdAges: ADULT hasResults: False
nctId: NCT06363773 id: RESTO-IMMUNO id: 2023-A02451-44 type: OTHER domain: ANSM briefTitle: A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer. acronym: RESTO-IMMUNO overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-09 date: 2026-06 date: 2024-04-12 date: 2024-04-17 name: Elsan class: OTHER briefSummary: This study aims at enrolling patients with solid tumors at metastatic stage, considered long responders to immunotherapy (\> 6 months) and displaying disease progression.
The objective of the study is to assess the ability of stereotactic radiotherapy to restore the lost efficacy of immunotherapy. In particular, the abscopal effect will be assessed, i.e. the action of irradiating a particular target lesion and observing an effect on other distant metastases. conditions: Metastatic Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Pilot, exploratory, prospective, monocentric study primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: Stereotactic Radiotherapy measure: Objective Response Rate according to iRECIST criteria at 3 months after stereotactic radiotherapy in patients with confirmed progression after initial response to immunotherapy. measure: Objective Response Rate according to RECIST 1.1 criteria at 3 months after stereotactic RT in patients with progression after initial response to immunotherapy. measure: Objective Response Rate according to iRECIST criteria up to 12 months after stereotactic radiotherapy in patients with confirmed progression after initial response to immunotherapy. measure: Objective Response Rate according to RECIST 1.1 criteria up to 12 months after stereotactic radiotherapy in patients with confirmed progression after initial response to immunotherapy. measure: Duration until new systemic treatment start. measure: Incidence of Adverse Events (safety) measure: Progression-Free Survival measure: Overall Survival measure: Objective Response Rate according to iRECIST criteria on the irradiated lesion only. measure: Objective Response Rate according to RECIST 1.1 criteria on the irradiated lesion only. measure: Objective Response Rate according to iRECIST criteria on all untreated lesion(s) (abscopal effect). measure: Objective Response Rate according to RECIST 1.1 criteria on all untreated lesion(s) (abscopal effect). measure: Objective Response Rate according to iRECIST criteria on each untreated lesion taken independently from others (abscopal effect). measure: Objective Response Rate according to RECIST 1.1 criteria on each untreated lesion taken independently from others (abscopal effect). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Clinical city: Soyaux state: Charente zip: 16800 country: France lat: 45.65 lon: 0.2 hasResults: False
nctId: NCT06363760 id: EDIT-301-LTFU-001 briefTitle: A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301 overallStatus: NOT_YET_RECRUITING date: 2024-06-04 date: 2040-08 date: 2040-08 date: 2024-04-12 date: 2024-04-12 name: Editas Medicine, Inc. class: INDUSTRY briefSummary: The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301. conditions: Sickle Cell Disease conditions: Transfusion-dependent Beta-Thalassemia conditions: Hemoglobinopathies studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 54 type: ESTIMATED name: Safety and efficacy assessments measure: Adverse events of special interest (AESI) measure: Adverse events of interest (AEI) measure: All-cause mortality measure: Adverse events (AEs) related to EDIT-301 measure: Serious adverse events (SAEs) measure: Proportion of SCD participants with severe vaso-occlusive events (sVOEs) over time post-EDIT-301 infusion measure: Proportion of SCD participants with vaso-occlusive events (VOEs) over time post-EDIT-301 infusion measure: Frequency of SCD-related transfusions over time post-EDIT-301 infusion for SCD participants measure: Proportion of TDT participants with sustained transfusion independence (TI) over time measure: Proportion of TDT participants with sustained transfusion reduction (TR) over time measure: Frequency of TDT-related transfusions over time post-EDIT-301 infusion for TDT participants measure: SCD and TDT: Percent of peripheral red blood cells (RBCs) containing HbF (F-cells) over time measure: SCD and TDT: Total hemoglobin (Hb) concentration (g/dL) over time measure: SCD and TDT: Proportion of alleles with intended genetic modification present in peripheral blood nucleated cells and bone marrow derived CD34+ over time measure: Average HbF (pg) per RBC over time for SCD participants measure: Complete Blood Count (CBC) red cell indices assay over time for SCD participants measure: Average HbF (pg) per F-cell over time for SCD participants measure: HbF and HbS concentration (g/dL) over time for SCD participants measure: The level of HbF production determined by fractionation of different forms of Hb (including but not limited to HbA, HbA2, HbC, HbD, HbE, and HbS) over time for SCD participants. measure: Percentage of HbF over total non-transfused total Hb (non-transfused total Hb refers to the total g/dL of all Hb variants, excluding HbA) over time for TDT participants. measure: HbF concentration (g/dL) over time for TDT participants measure: Iron overload of TDT participants measure: Proportion of TDT participants receiving iron chelation therapy over time. sex: ALL minimumAge: 12 Years maximumAge: 50 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06363747 id: 123456 briefTitle: The Medically Reproducing Bariatric Surgery (MRB) II Study overallStatus: NOT_YET_RECRUITING date: 2024-06-03 date: 2025-06-03 date: 2025-06-03 date: 2024-04-12 date: 2024-04-15 name: Durham VA Medical Center class: FED name: Société des Produits Nestlé (SPN) briefSummary: Roux-en-Y (RYGB) gastric bypass reduces the size and capacity of the stomach and bypasses a portion of the small intestine which leads to decreased food intake and higher levels of a gut hormone called GLP-1 (glucagon-like-peptide-1). These changes lead to weight loss, improved blood sugars and often remission of type 2 diabetes but most patients do not qualify or want surgery. The investigators are searching for ways to make the beneficial effects of RYGB available to most type 2 diabetes patients rather than a select few that undergo RYGB.
The investigators believe that parts of RYGB can be medically reproduced through a combination of diet and medicine. Once weekly injectable GLP-1 medicine that leads to weight loss and improved blood sugar control in type 2 diabetes are now FDA approved. Optifast is a medically supervised diet that safely reduces calorie intake to 800 calories per day for three months by replacing normal meals with specially prepared bars and shakes which leads to weight loss and improved blood sugar control in type 2 diabetes. Normal meals are then gradually reintroduced over 6 weeks and the bars/shakes are stopped. The investigators hypothesize that Optifast (diet) + once weekly GLP-1 will lead to weight loss and improvement in blood sugar control in type 2 diabetes similar to what is seen after RYGB. conditions: Type 2 Diabetes conditions: Obesity studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Control--\[GLP-1 agonist +/- DM2 meds + medical management + nutritional/behavioral counseling\] Experimental---\[Optifast + GLP-1 agonist + medical management + nutritional/behavioral counseling\] primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Very Low Calorie Diet measure: Glycemic Control measure: Weight lost measure: Medication Intensity measure: Health Related Quality of Life measure: Symptom Item Checklist sex: ALL minimumAge: 25 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Greenville VA Health Care Center city: Greenville state: North Carolina zip: 27834 country: United States lat: 35.61266 lon: -77.36635 hasResults: False
nctId: NCT06363734 id: DAL20240409 briefTitle: Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial overallStatus: RECRUITING date: 2024-04-09 date: 2025-12-15 date: 2026-12-31 date: 2024-04-12 date: 2024-04-16 name: Tianjin Medical University Cancer Institute and Hospital class: OTHER briefSummary: This study is a prospective, single-arm, phase II trial. It is aimed to evaluate the efficacy and safety of the combination of osimertinib and dalpiciclib in patients with EGFR-mutant, CDK4/6 pathway aberrant, advanced NSCLC following acquired resistance to third-generation EGFR TKI. conditions: Non-small Cell Lung Cancer conditions: EGFR Activating Mutation conditions: Cell Cycle Deregulation conditions: EGFR-TKI Resistant Mutation studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: Osimertinib plus Dalpiciclib measure: Objective Response Rate (ORR) measure: disease control rate (DCR) measure: Duration of Response (DoR) measure: Progression Free Survival (PFS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Thoracic Medical Oncology, Tianjin Medical University Cancer Hospital status: RECRUITING city: Tianjin state: Tianjin zip: 300060 country: China name: Peng Chen, M.D. role: CONTACT phone: +86-22-23340123 phoneExt: 3201 email: chenpeng@tjmuch.com name: Peng Chen, M.D. role: PRINCIPAL_INVESTIGATOR lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06363721 id: DFH00125 briefTitle: A Pilot Study of a Commercially-available Oil Rinse Product (PerioPull™) on Markers of Dental Health overallStatus: RECRUITING date: 2024-04 date: 2024-12 date: 2024-12 date: 2024-04-12 date: 2024-04-12 name: Designs for Health class: INDUSTRY briefSummary: The primary purpose of this study is to evaluate the impact of a commercially-available oil rinse product (PerioPull™) on parameters of dental health among a sample of adults. PerioPull™ is commercially available and sold primarily from clinicians' offices.
A 12-week pilot study will be conducted to achieve the purpose of this study. The research team hypothesizes that PerioPull™ will improve a variety of validated markers of dental health that are commonly used in clinical practice. conditions: Oral Health studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The proposed study is a 12-week pilot study of PerioPull™. Eligible participants will be recruited from within the clinical practice of the periodontist. All study outcomes will be measurements and testing during three dental visits spaced 6 weeks apart. These are typical assessments in routine clinical practice. All study outcomes are described in detail in an ensuing section. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 18 type: ESTIMATED name: PerioPull™ measure: Plaque Index measure: Gingival Index measure: Pocket Depth measure: Intraoral Photos measure: MyPerioPath® sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Julian Center for Comprehensive Dentistry status: RECRUITING city: Ellicott City state: Maryland zip: 21042 country: United States name: Eugene Sambataro, DDS role: CONTACT phone: 410-834-0796 email: drsam@julianctr.com name: Eugene Sambataro, DDS role: PRINCIPAL_INVESTIGATOR name: Chris D'Adamo, PhD role: SUB_INVESTIGATOR name: Michael Jurgelewicz, DC role: SUB_INVESTIGATOR name: David Brady, ND, DC role: SUB_INVESTIGATOR lat: 39.26733 lon: -76.79831 hasResults: False
nctId: NCT06363708 id: 2024050 briefTitle: Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-12-01 date: 2026-06-30 date: 2024-04-12 date: 2024-04-12 name: Zhongnan Hospital class: OTHER briefSummary: The goal of this clinical trial is to evaluate the efficacy and safety of tislelizumab in combination with chemotherapy as a neoadjuvant treatment for advanced endometrial cancer. conditions: Endometrial Neoplasms studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Tislelizumab name: Paclitaxel name: Carboplatin measure: R0 resection rate (R0 %) measure: Pathological complete response rate (pCR%） measure: Objective Response Rate (ORR%) measure: Progression free survival (PFS) measure: Recurrence free survival (RFS) measure: Overall survival (OS) measure: Incidence and severity of adverse events as assessed by the NCI-CTCAE v5.0 sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Central Hospital of Wuhan city: Wuhan state: Hubei zip: 430014 country: China name: Xun Tian, MD,PhD role: CONTACT phone: 15327205656 email: tianxun@126.com lat: 30.58333 lon: 114.26667 facility: Zhongnan Hospital of Wuhan University city: Wuhan state: Hubei zip: 430062 country: China name: Zheng Hu, MD,PhD role: CONTACT phone: 13632120686 email: Huzheng1988@163.com lat: 30.58333 lon: 114.26667 facility: Hubei maternal and child health care hospital city: Wuhan state: Hubei zip: 430070 country: China name: QuanFu Ma, MD,PhD role: CONTACT phone: 13728133014 email: dm626925@126.com lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06363695 id: 131-22 id: 1R01HD112043-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R01HD112043-01 briefTitle: Building Community Health Volunteers' Capacity to Support Parents With Young Children With SafeCare Kenya overallStatus: RECRUITING date: 2024-03-14 date: 2028-01 date: 2028-05 date: 2024-04-12 date: 2024-04-12 name: Pacific University class: OTHER name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) name: Africa Mental Health Research and Training Foundation name: Georgia State University briefSummary: The goal of this clinical trial is to implement and examine the impact of SafeCare Kenya, an adapted parenting program, to improve parents' skills and knowledge related to the care of their children between the ages of 18 months and 5 years old. The main questions it aims to answer are: